Iran is pushing boundaries amid rising tensions in the Gulf, but President Trump has so far not been "compelled" to retaliate militarily, analysts say.World Politicsread more
The U.K. will find out who its next prime minister will be on Tuesday.Europe Politicsread more
UBS announced a net profit of $1.4 billion for the second quarter of 2019.Earningsread more
Japan and South Korea are part of a complex and tightly linked supply chain that produces electronic goods such as smartphones and laptops.Technologyread more
Michael Kugelman from the U.S.-based Wilson Center says other issues take precedence in the bilateral dialogue between the United States and Pakistan — namely, Afghanistan and...Asia Politicsread more
Beijing says it can still meet its 2019 growth target of between 6% and 6.5% and continues to roll out stimulus measures to prop up activity. China set a 2019 industrial...China Economyread more
A different oil pricing dynamic has been evolving with new supply calculations based on the U.S. as the world's largest producer.Market Insiderread more
The Massachusetts senator's alarm-sounding on consumer debt neglects to measure it against the growth in the economy and the ability to pay.Economyread more
Stocks in Asia Pacific edged up on Tuesday, as investors await closely-watched central bank meetings in the coming days.Asia Marketsread more
More than half of Venezuela's 23 states lost power on Monday, according to Reuters witnesses and reports on social media, a blackout the government blamed on an...World Politicsread more
Equifax will give consumers a range of options for monitoring their credit or making claims of fraud or data misuse, part of a $425 million restitution fund.Technologyread more
Mylan said it would launch the first generic version of its allergy auto-injector EpiPen at half the price of the branded product, but a chief pharmacy officer says that the generic drug could end up costing patients even more.
"Most generic companies don't allow co-pay cards," said Scott Knoer, chief pharmacy officer at the Cleveland Clinic.
He explained on CNBC's "Closing Bell " that the unavailability of a co-pay card for generic drugs or even with a high-deductible insurance plan increases the chances for a patient to pay out of pocket.
Knoer viewed Mylan's offering of a generic brand as the company's way to "command both brand and potentially the generic market," while the competitors struggle to break into the market.
Mylan has claimed that pharmacies are to blame for the higher costs of branded drugs. Knoer's said he believes "that statement is almost as egregious as the pricing increases that they've done."
Mylan said it expects to launch the generic alternative at a list price of $300, compared to the branded list price of $600. Knoer said his clinics have kits with syringes and Epinephrine administered by trained nurses to help to keep cost low.
"It costs us about $15 dollars," said Knoer, on the actual cost per vial of Epinephrine. However, the difference in pricing comes down to the way the drug is administered, making a $15 commercial option "really challenging."
-Reuters contributed to this report